omeprazole has been researched along with digoxin in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (13.89) | 18.2507 |
| 2000's | 13 (36.11) | 29.6817 |
| 2010's | 15 (41.67) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Cohen, AF; Hoogkamer, H; Kroon, R; Schoemaker, R; van Vliet, A | 1 |
| Andersson, T; Jedema, JN; Jonkman, JH; Oosterhuis, B; Zuiderwijk, PB | 1 |
| Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K | 1 |
| Bliesath, H; Hartmann, M; Huber, R; Koch, HJ; Kunz, K; Steinijans, VW; Wurst, W | 2 |
| Fromm, MF; Klotz, U; Pauli-Magnus, C; Rekersbrink, S | 1 |
| Bermejo, MV; Cantón, E; Orero, A; Pemán, J; Velert, MM | 1 |
| Karlstadt, RG; Walker, K | 1 |
| Delattre, M; Felicio, L; Le, GH; Morreale, AP; Okino, L; Plowman, BK; Schaefer, MG | 1 |
| Carlson, GL; Collett, A; Harwood, MD; Tanianis-Hughes, J; Warhurst, G | 1 |
| Haas, SJ | 1 |
| Cragin, DJ; Kiley, CA; Roth, BJ | 1 |
| Jerome, L | 1 |
| Barr, M; Gabello, M; Mullin, JM; Valenzano, MC; Zurbach, P | 1 |
| Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM | 1 |
| Chong, E; Kalia, V; Willsie, S; Winkle, P | 1 |
| Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Baptista, TM; Barros, RB; Marques, EB; Scaramello, CB; Souza, FC | 1 |
| Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A | 1 |
| Balzan, D; Callus, R; Delicata, L; Felice, T | 1 |
| Balazki, P; Baumgart, J; Beelen, DW; Böhm, S; Hemmelmann, C; Hilger, RA; Martins, FS; Ring, A; Schaller, S | 1 |
| Ang, DSW; Ang, TL; Benech, H; Koo, SH; Lee, EJD; Pruvost, A; Soon, GH | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
2 review(s) available for omeprazole and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Lack of pantoprazole drug interactions in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin | 1994 |
11 trial(s) available for omeprazole and digoxin
| Article | Year |
|---|---|
Influence of gastric acidity on the bioavailability of digoxin.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Digoxin; Double-Blind Method; Gastric Acid; Humans; Immunoenzyme Techniques; Male; Omeprazole; Pentagastrin; Random Allocation | 1991 |
Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.
Topics: Administration, Oral; Adult; Biological Availability; Digoxin; Drug Interactions; Humans; Male; Omeprazole | 1991 |
Lack of pantoprazole drug interactions in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin | 1994 |
Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Blood Pressure; Cross-Over Studies; Digoxin; Drug Interactions; Electrocardiography; Enzyme Inhibitors; Female; Heart Rate; Humans; Male; Omeprazole; Pantoprazole; Single-Blind Method; Sodium-Potassium-Exchanging ATPase; Sulfoxides | 1995 |
Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Benzimidazoles; Cardiotonic Agents; Cross-Over Studies; Digoxin; Drug Interactions; Electrocardiography; Enzyme Inhibitors; Female; Humans; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides | 1996 |
Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Digoxin; Drug Interactions; Formularies, Hospital as Topic; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2003 |
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult | 2014 |
Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Area Under Curve; Cardiotonic Agents; Chelating Agents; Digoxin; Diuretics; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Ferric Compounds; Furosemide; Half-Life; Healthy Volunteers; Humans; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Risk Assessment; Sucrose; Warfarin; Young Adult | 2014 |
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Topics: Adult; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Felodipine; Female; Genotype; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2014 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
Topics: Caffeine; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Tolbutamide | 2022 |
24 other study(ies) available for omeprazole and digoxin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Transport; Caco-2 Cells; Digoxin; Drug Interactions; Enzyme Inhibitors; Epithelial Cells; Humans; Lansoprazole; LLC-PK1 Cells; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Sulfoxides; Swine | 2001 |
[Influence of ion pump-inhibiting drugs on the accumulation of ofloxacin and grepafloxacin in human polymorphonuclear leukocytes].
Topics: Anti-Infective Agents; Calcium Channel Blockers; Digoxin; Enzyme Inhibitors; Fluoroquinolones; Humans; Ion Pumps; Neutrophils; Ofloxacin; Omeprazole; Piperazines; Verapamil | 2002 |
Update on prescribing information for pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Digoxin; Drug Interactions; Esophagitis; Humans; Nifedipine; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2003 |
Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Digoxin; Drug Interactions; Humans; Intestines; Male; Mice; Omeprazole | 2005 |
Is this medicine really involved in a drug interaction?
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Digoxin; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inhibitors; Risk Factors; Warfarin | 2007 |
Omeprazole-associated digoxin toxicity.
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Drug Interactions; Enzyme Inhibitors; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Immunoglobulin Fab Fragments; Omeprazole; Poisoning; Tachycardia, Paroxysmal | 2007 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardiotonic Agents; Cataract; Cataract Extraction; Cholecystectomy; Chronic Disease; Citalopram; Digoxin; Female; gamma-Aminobutyric Acid; Heart Failure; Humans; Hypertension; Hysterectomy; Lorazepam; Middle Aged; Mitral Valve Insufficiency; Omeprazole; Ovarian Neoplasms; Pain; Pregabalin; Sterilization, Tubal; Stomach Diseases; Vulvar Diseases | 2007 |
Omeprazole induces gastric permeability to digoxin.
Topics: Animals; Chromatography, Thin Layer; Digoxin; Electrophysiology; Gastric Mucosa; Hydrogen-Ion Concentration; In Vitro Techniques; Male; Omeprazole; Permeability; Phenytoin; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tight Junctions | 2010 |
Omeprazole does not modulate pharmacokinetic of digoxin in patients with heart failure.
Topics: Adult; Cardiotonic Agents; Digoxin; Drug Interactions; Heart Failure; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Young Adult | 2015 |
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin | 2017 |
Digoxin toxicity precipitated by Helicobacter pylori eradication therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Amoxicillin; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Atrial Fibrillation; Bradycardia; Bundle-Branch Block; Clarithromycin; Digoxin; Drug Interactions; Electrocardiography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hyperkalemia; Immunoglobulin Fab Fragments; Omeprazole; Tachycardia, Ventricular | 2019 |
Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Busulfan; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations | 2022 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |